عنوان المقالة:The Design and Evaluation of a Novel Monoamine Oxidase B Inhibitor Through in Silico Approach The Design and Evaluation of a Novel Monoamine Oxidase B Inhibitor Through in Silico Approach
محمد عباس حسن | Mohammed Abbas Hasan | 7495
نوع النشر
مجلة علمية
المؤلفون بالعربي
Hasanain Abdulhameed Odhar , Safaa Muhsen Kareem , Mohammed Ridha A Alhaideri , Mohammed Abbas Hasan , Werner J Geldenhuys
المؤلفون بالإنجليزي
Hasanain Abdulhameed Odhar , Safaa Muhsen Kareem , Mohammed Ridha A Alhaideri , Mohammed Abbas Hasan , Werner J Geldenhuys
الملخص العربي
Parkinson’s disease is an age related neurodegenerative disease. Pioglitazone is a Peroxisome proliferator-activated receptor gamma agonist that has been shown to display a neuroprotective effect in parkinsonian models (1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine treated mice). This effect was partially attributed to the ability of thiazolidinedione (TZD) moiety in Pioglitazone to selectively inhibit monoamine oxidase B (MAO-B) enzyme. In the current study, we screened several thiazolidine containing compounds against MAO-B enzyme both in silico and in vitro. Based on the resulted data and information from previous literatures, we were able to design a novel scaffold for MAO-B inhibitors. This scaffold (compound 5482440) was able to inhibit MAO-B enzyme with IC50 value of 1.447 µM. Structure-based virtual analysis showed that this compound was able to participate in water-bridge formation and obtain an extended conformation within MAO-B active site
الملخص الانجليزي
Parkinson’s disease is an age related neurodegenerative disease. Pioglitazone is a Peroxisome proliferator-activated receptor gamma agonist that has been shown to display a neuroprotective effect in parkinsonian models (1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine treated mice). This effect was partially attributed to the ability of thiazolidinedione (TZD) moiety in Pioglitazone to selectively inhibit monoamine oxidase B (MAO-B) enzyme. In the current study, we screened several thiazolidine containing compounds against MAO-B enzyme both in silico and in vitro. Based on the resulted data and information from previous literatures, we were able to design a novel scaffold for MAO-B inhibitors. This scaffold (compound 5482440) was able to inhibit MAO-B enzyme with IC50 value of 1.447 µM. Structure-based virtual analysis showed that this compound was able to participate in water-bridge formation and obtain an extended conformation within MAO-B active site
تاريخ النشر
01/06/2019
الناشر
International Journal of Pharmaceutical Quality Assurance
رقم المجلد
10
رقم العدد
2
ISSN/ISBN
0975 9506
الصفحات
6
رابط الملف
تحميل (438 مرات التحميل)
رابط خارجي
https://ijpqa.com/volume10issue2/
الكلمات المفتاحية
Parkinson’s disease; thiazolidine; scaffold; MAO-B; docking.
رجوع